CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 639-652

  McCleland, Mark L ^a   Mesh, Kathryn ^a   Lorenzana, Edward ^a   Chopra, Vivek S ^a   Segal, Ehud ^a   Watanabe, Colin ^a   Haley, Benjamin ^a   Mayba, Oleg ^a   Yaylaoglu, Murat ^a   Gnad, Florian ^a   Firestein, Ron ^a,b  

^a GENENTECH INC   (United States)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BET PROTEIN BRD4; COLON CANCER ASSOCIATED TRANSCRIPT 1; DOXYCYCLINE; LONG UNTRANSLATED RNA; PROTEIN; RNA; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CCAT1 LONG NONCODING RNA, HUMAN; DNA; MYC PROTEIN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; TUMOR MARKER;

AGED; ARTICLE; CANCER GROWTH; CELL GROWTH; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; ESSENTIAL GENE; FEMALE; GENOMICS; HUMAN; HUMAN CELL; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL TUMOR; DNA METHYLATION; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; AZEPINES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, LONG NONCODING; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84956888100     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83265     Document Type: Article

References (80)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191-197.
2. Fearon ER. Molecular genetics of colorectal cancer. Ann N Y Acad Sci. 1995;768:101-110.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
4. Sillars-Hardebol AH, et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol. 2010;31(2):89-96.
5. Issa JP. Colon cancer: it's CIN or CIMP. Clin Cancer Res. 2008;14(19):5939-5940.
6. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13-27.
7. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681-8686.
8. Adler AS, et al. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev. 2014;28(10):1068-1084.
9. Salari K, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci U S A. 2012;109(46):E3196-E3205.
10. Firestein R, Hahn WC. Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res. 2009;69(20):7899-7901.
11. Dulak AM, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012;72(17):4383-4393.
12. Fearon ER, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247(4938):49-56.
13. Powell SM, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235-237.
14. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
15. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-37.
16. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8(12):686-700.
17. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol. 2013;25(2):177-183.
18. Teo JL, Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev. 2010;62(12):1149-1155.
19. Blythe SA, Cha SW, Tadjuidje E, Heasman J, Klein PS. beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8 methyltransferase, Prmt2. Dev Cell. 2010;19(2):220-231.
20. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics. 2009;4(5):307-312.
21. Jiang X, et al. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008;13(6):529-541.
22. Suzuki H, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36(4):417-422.
23. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005; 2(suppl 1):S4-S11.
24. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-2054.
25. Issa JP. The epigenetics of colorectal cancer. Ann N Y Acad Sci. 2000;910:140-153.
26. Suzuki H, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31(2):141-149.
27. Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol. 2002;12(5):331-337.
28. Wee S, et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014;1309:30-36.
29. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014;124(1):56-63.
30. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours - lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256-266.
31. Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol. 2014;88(9):1651-1668.
32. Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
33. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337-356.
34. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
35. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471.
36. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-826.
37. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131-149.
38. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343(6166):80-84.
39. Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-87.
40. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. 2014;32(3):267-273.
41. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728-736.
42. Rodriguez RM, et al. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med (Berl). 2012;90(5):587-595.
43. Hu Y, et al. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci. 2015;16(1):1928-1948.
44. Floyd SR, et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013;498(7453):246-250.
45. Wang R, Li Q, Helfer CM, Jiao J, You J. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J Biol Chem. 2012;287(14):10738-10752.
46. Yang Z, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535-545.
47. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523-534.
48. Mochizuki K, et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem. 2008;283(14):9040-9048.
49. Alsarraj J, et al. Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition-and stem cell-like conversion. Cancer Res. 2011;71(8):3121-3131.
50. Zuber J, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
51. Gray DC, et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol. 2007;7:61.
52. Ribbing J, Nyberg J, Caster O, Jonsson EN. The lasso - a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2007;34(4):485-517.
53. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9(3):305-314.
54. Lleras RA, et al. Hypermethylation of a cluster of Kruppel-type zinc finger protein genes on chromosome 19q13 in oropharyngeal squamous cell carcinoma. Am J Pathol. 2011;178(5):1965-1974.
55. Mirguet O, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem. 2013;56(19):7501-7515.
56. Fearon ER, Dang CV. Cancer genetics: tumor suppressor meets oncogene. Curr Biol. 1999;9(2):R62-R65.
57. Sansom OJ, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007;446(7136):676-679.
58. Whyte WA, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307-319.
59. Dowen JM, et al. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell. 2014;159(2):374-387.
60. Mansour MR, et al. Oncogene regulation. Science. 2014;346(6215):1373-1377.
61. Ma MZ, et al. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015;6:e1583.
62. Mizrahi I, et al. Colon Cancer Associated Transcript-1 (CCAT1) expression in adenocarcinoma of the stomach. J Cancer. 2015;6(2):105-110.
63. Xiang JF, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24(5):513-531.
64. Asangani IA, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278-282.
65. Kim TK, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010;465(7295):182-187.
66. Wang D, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390-394.
67. Kanno T, et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol. 2014;21(12):1047-1057.
68. Klijn C, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33(3):306-312.
69. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012;109(47):19408-19413.
70. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703-718.
71. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
72. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367(7):647-657.
73. Boettcher M, Hoheisel JD. Pooled RNAi screens - technical and biological aspects. Curr Genomics. 2010;11(3):162-167.
74. Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle. 2012;11(23):4344-4351.
75. Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014;455(1-2):35-42.
76. Phipps AI, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77-87 e72.
77. Cheng YW, et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008;14(19):6005-6013.
78. Younger ST, Rinn JL. 'Lnc'-ing enhancers to MYC regulation. Cell Res. 2014;24(6):643-644.
79. McCleland ML, et al. Cdk8 deletion in the Apc murine tumour model represses EZH2 activity and accelerates tumourigenesis [published online ahead of print August 3, 2015 J Pathol. doi:10.1002/path.4596.
80. Adler AS, et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res. 2012;72(8):2129-2139.